Zobrazeno 1 - 10
of 36
pro vyhledávání: '"F R Ahmann"'
Autor:
David S. Alberts, Mary E. Reid, M. S. Stratton, James R. Marshall, F. R. Ahmann, F. E. Minter, B. K. Monroe, G. Schwartzberg
Publikováno v:
Anti-Cancer Drugs. 14:595-600
Impediment of the promotion and progression stages of carcinogenesis of the prostate could have a profound impact on treatment choice and prognosis for prostate cancer. Efficacious chemopreventive agents that elicit their activity by slowing the proc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::036a7d83cf658adfcd0e223c704df76a
https://doi.org/10.1097/00001813-200309000-00004
https://doi.org/10.1097/00001813-200309000-00004
Autor:
F. R. Ahmann, James R. Marshall, David S. Alberts, Mary E. Reid, M. S. Stratton, B. K. Monroe, F. E. Minter, G. Schwartzberg
Publikováno v:
Anti-Cancer Drugs. 14:589-594
Epidemiological and clinical studies suggesting a significant inverse relationship between intake of dietary selenium and overall cancer risk have led to initiation of a randomized, placebo-controlled, phase III clinical trial testing the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::775e7050c93c39c4cb02ab7362fc8600
https://doi.org/10.1097/00001813-200309000-00003
https://doi.org/10.1097/00001813-200309000-00003
Autor:
S J Houston, A Pecking, I. Resche, K A Harrison, F M Grund, A Bertrand, Eduardo Orihuela, Peter J. Ell, R H Reid, G L Purnell, F R Ahmann, B D Collier, J H McKillop, R A Lerski, F D Thomas, Donald P. Quick, Aldo N. Serafini
Publikováno v:
Journal of Clinical Oncology. 16:1574-1581
PURPOSE To evaluate the effectiveness and safety of samarium-153 (153Sm) lexidronam (EDTMP) in a double-blind, placebo-controlled study. PATIENTS AND METHODS Patients with painful bone metastases secondary to a variety of primary malignancies were ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763170caa8da62e82506f50f52e68986
https://doi.org/10.1200/jco.1998.16.4.1574
https://doi.org/10.1200/jco.1998.16.4.1574
Autor:
T. Whiteside, Robert Dreicer, Allan J. Pantuck, Nadine Bizouarne, Walter M. Stadler, Bruce Acres, F. R. Ahmann, P. Squiban, Jean-Marc Limacher
Publikováno v:
Investigational new drugs. 27(4)
Purpose: TG4010 is a recombinant MVA vector expressing the tumor-associated antigen MUC1 and IL2. We explored the effect two schedules of TG4010 on PSA in men with PSA progression. Patients and methods: A randomized phase II trial was conducted in 40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64fdfefa7642540557d07bf1b19289e4
https://pubmed.ncbi.nlm.nih.gov/18931824
https://pubmed.ncbi.nlm.nih.gov/18931824
Publikováno v:
The Journal of urology. 157(5)
We evaluated the 3-year longitudinal changes in serial serum prostate specific antigen (PSA) levels in men with an initial PSA of 4.0 ng./ml. or less and no suspicion of prostate cancer.A total of 760 men with an initial PSA of 4.0 ng./ml. or less pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a7044a47618807072d54ef584a545024
https://pubmed.ncbi.nlm.nih.gov/9112520
https://pubmed.ncbi.nlm.nih.gov/9112520
Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain
Autor:
G T, Krishnamurthy, F M, Swailem, S C, Srivastava, H L, Atkins, L J, Simpson, T K, Walsh, F R, Ahmann, G E, Meinken, J H, Shah
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 38(2)
Biokinetics and imaging characteristics of 117mSn(4+)DTPA have been studied in patients with metastatic bone pain.Seventeen patients with bone pain due to metastasis were given three dose levels: 180 microCi/kg (6.66 MBq/kg), 229 microCi/kg (8.47 MBq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ae3318178dfdb12f81721a683f804e6
https://pubmed.ncbi.nlm.nih.gov/9025743
https://pubmed.ncbi.nlm.nih.gov/9025743
Publikováno v:
The Journal of urology. 155(4)
We determined whether 12 weeks of neoadjuvant testicular androgen ablation therapy using a luteinizing hormone-releasing hormone agonist could improve pathological outcomes in men undergoing radical retropubic prostatectomy for clinically localized (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::846b0fdb362e4a080d95857a8c0f16c1
https://pubmed.ncbi.nlm.nih.gov/8632574
https://pubmed.ncbi.nlm.nih.gov/8632574
Publikováno v:
Cancer. 71(11)
Carcinoembryonic antigen (CEA) is a well-described human tumor-associated antigen most useful clinically in colon cancer. However, the clinical usefulness of CEA is limited by the marker's overall poor specificity and low sensitivity in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b93f5c530abaef4678a72447a82ddb51
https://pubmed.ncbi.nlm.nih.gov/8490911
https://pubmed.ncbi.nlm.nih.gov/8490911
Autor:
R L, Stephens, P, Goodman, E D, Crawford, C F, Spicer, B A, Lowe, F R, Ahmann, R, Chapman, R B, Natale
Publikováno v:
Investigational new drugs. 8
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64b01ef0356a06d104bc84bd60f09afd
https://pubmed.ncbi.nlm.nih.gov/2143177
https://pubmed.ncbi.nlm.nih.gov/2143177
Autor:
L. Duvillie, C. Terret, G. Wilding, C. Puzon, A. Shah, G. Weems, Stéphane Culine, H. Raftopoulos, F. R. Ahmann, K. Papadopoulos
Publikováno v:
Journal of Clinical Oncology. 23:2042-2042
2042 Background: Irofulven (IROF), a semisynthetic derivative of the natural product illudin S, is a novel DNA binding agent that has demonstrated antitumor activity in patients (pts) with a variet...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83a504ebda402a2425d1c79cadb85436
https://doi.org/10.1200/jco.2005.23.16_suppl.2042
https://doi.org/10.1200/jco.2005.23.16_suppl.2042